Quick Answer
GYRE THERAPEUTICS, INC. reported Net Income Loss of $9.88 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -44.8% in Net Income Loss from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: -$8.14 million | Q3 2014: -$1.50 million | Q4 2014: -$1.30 million | Q1 2015: -$2.86 million | Q2 2015: -$1.72 million | Q3 2015: -$5.05 million | Q4 2015: -$5.13 million | Q1 2016: -$3.59 million | Q2 2016: -$4.83 million | Q3 2016: -$4.77 million | Q1 2017: -$4.14 million | Q2 2017: -$5.88 million | Q3 2017: -$5.79 million | Q1 2018: -$5.04 million | Q2 2018: -$6.48 million | Q3 2018: -$7.69 million | Q1 2019: -$15.08 million | Q2 2019: -$13.78 million | Q3 2019: -$12.71 million | Q1 2020: -$4.05 million | Q2 2020: -$17.25 million | Q3 2020: -$16.03 million | Q1 2021: -$22.44 million | Q2 2021: -$19.93 million | Q3 2021: -$25.24 million | Q1 2022: -$14.54 million | Q2 2022: $51.63 million | Q3 2022: -$4.88 million | Q1 2023: $4.22 million | Q2 2023: $3.77 million | Q3 2023: $7.51 million | Q1 2024: $9.94 million | Q2 2024: $4.54 million | Q3 2024: $2.86 million | Q1 2025: $3.73 million | Q2 2025: $1.58 million | Q3 2025: $5.94 million.
- Over the full 17 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Net Income Loss has grown by 125.1%.
- Historical annual values: Fiscal year 2025: $9.88 million | Fiscal year 2024: $17.90 million | Fiscal year 2023: -$85.48 million | Fiscal year 2022: $4.31 million | Fiscal year 2021: -$87.93 million | Fiscal year 2020: -$56.24 million | Fiscal year 2019: -$55.18 million | Fiscal year 2018: -$30.06 million | Fiscal year 2017: -$21.56 million | Fiscal year 2016: -$16.95 million | Fiscal year 2015: -$14.76 million | Fiscal year 2014: -$6.61 million | Fiscal year 2013: -$9.97 million | Fiscal year 2012: -$7.00 million | Fiscal year 2011: -$8.53 million | Fiscal year 2010: $10.90 million | Fiscal year 2009: -$39.40 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: